# Idorsia Pharmaceuticals Ltd.: Phase 3 study completed, 107 enrolled (Fabry Disease)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Idorsia Pharmaceuticals Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease |
| NCT ID | NCT03737214 |
| Phase | Phase 3 |
| Status | completed |
| Conditions | Fabry Disease |
| Intervention types | drug |
| Target enrollment | 107 |
| Site countries | United States, Australia, Austria, Belgium, Canada, France, Germany, Netherlands, Norway, Poland, Spain, Switzerland |
| Posted | 2018-11-09 |
| Planned start | 2018-12-18 |
| Event | Completed |
| Event date | 2026-10-06 |
| Last update posted | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 3: multi-site, larger budget.
- 107 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03737214). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.